UC San Diego Researchers Launch Combination Drug Trial to Eradicate B-Cell Malignancies

on .

Newswise imageFueled by a multimillion dollar grant from the state's stem cell agency, researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have launched a phase Ib/II clinical trial to evaluate the combined effectiveness of a standard of care drug with a novel monoclonal antibody that target B-cell malignancies, which include leukemias and lymphomas.

Read full article on newswise.com